Proteome-wide analysis of T-cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals a unique transcriptional and functional profile.

T cells adaptive immunity cellular immunity immunology immunotherapy infectious diseases innate immune cells lymphocytes viral infection

Journal

Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268

Informations de publication

Date de publication:
2020
Historique:
received: 01 07 2019
revised: 15 12 2019
accepted: 19 12 2019
entrez: 21 1 2020
pubmed: 21 1 2020
medline: 21 1 2020
Statut: epublish

Résumé

Cellular immunity against BK polyomavirus (BKV)-encoded antigens plays a crucial role in long-term protection against virus-associated pathogenesis in transplant recipients. However, in-depth understanding on dynamics of these cellular immune responses is required to develop better immune monitoring and immunotherapeutic strategies. Here, we have conducted a proteome-wide analysis of BKV-specific T-cell responses in a cohort of 53 healthy individuals and 26 kidney transplant recipients to delineate the functional and transcriptional profile of these effector cells and compared these characteristics to T cells directed against cytomegalovirus, which is also known to cause significant morbidity in transplant recipients. Profiling of BKV-specific CD4 These observations provide an important platform for the future development of immune monitoring and adoptive T-cell therapy strategies for BKV-associated diseases in transplant recipients, which may also be exploited for similar therapeutic value in JCV-associated clinical complications.

Identifiants

pubmed: 31956413
doi: 10.1002/cti2.1102
pii: CTI21102
pmc: PMC6960379
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e01102

Informations de copyright

© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.

Déclaration de conflit d'intérêts

GA, BTA and RK are listed as inventors on international patent application that includes multiple BKV epitopes. RK and CS are consultants for Atara Biotherapeutics and received research support from Atara Biotherapeutics.

Références

Nucleic Acids Res. 2013 Jan;41(Database issue):D1228-33
pubmed: 23180781
Clin Vaccine Immunol. 2008 Oct;15(10):1564-71
pubmed: 18753339
Transplantation. 2009 Mar 15;87(5):621-30
pubmed: 19295303
J Infect Dis. 2002 Jun 15;185(12):1709-16
pubmed: 12085315
J Virol. 2015 May;89(9):5110-23
pubmed: 25717102
Transpl Infect Dis. 2006 Jun;8(2):86-94
pubmed: 16734631
Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85
pubmed: 26372850
J Virol. 2005 Sep;79(17):11170-8
pubmed: 16103168
Nat Immunol. 2011 May 29;12(7):663-71
pubmed: 21623380
Clin Infect Dis. 2019 Feb 1;68(4):632-640
pubmed: 29982441
Virology. 2006 Jun 20;350(1):128-36
pubmed: 16600320
Science. 2003 Nov 7;302(5647):1041-3
pubmed: 14605368
Transplantation. 2011 Nov 27;92(10):1077-84
pubmed: 22002347
J Virol. 2013 Sep;87(18):10263-72
pubmed: 23864628
PLoS Pathog. 2016 Oct 10;12(10):e1005903
pubmed: 27723787
J Infect Dis. 2009 Mar 15;199(6):837-46
pubmed: 19434930
Am J Transplant. 2014 Jun;14(6):1334-45
pubmed: 24726000
Nat Immunol. 2005 Dec;6(12):1236-44
pubmed: 16273099
N Engl J Med. 2002 Aug 15;347(7):488-96
pubmed: 12181403
PLoS Med. 2008 May 6;5(5):e100
pubmed: 18462013
J Virol. 2009 Jun;83(12):6192-8
pubmed: 19357166
Cancer Res. 2014 Jul 1;74(13):3466-76
pubmed: 24795429
Am J Transplant. 2007 Dec;7(12):2727-35
pubmed: 17908275
J Immunol. 2007 Jul 1;179(1):141-53
pubmed: 17579032
Nat Biotechnol. 2008 Mar;26(3):317-25
pubmed: 18278033
Am J Transplant. 2007 May;7(5):1131-9
pubmed: 17359507
Am J Transplant. 2011 Nov;11(11):2443-52
pubmed: 21831150
Transplantation. 2004 Oct 27;78(8):1229-32
pubmed: 15502726
Am J Transplant. 2013 Mar;13 Suppl 4:179-88
pubmed: 23465010
J Virol. 1999 Oct;73(10):8179-84
pubmed: 10482568
Neth J Med. 2012 May;70(4):172-83
pubmed: 22641625
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
Adv Exp Med Biol. 2006;577:19-45
pubmed: 16626025
Eur J Immunol. 2004 Dec;34(12):3525-33
pubmed: 15484193

Auteurs

George R Ambalathingal (GR)

QIMR Berghofer Centre for Immunotherapy and Vaccine Development Tumour Immunology Laboratory QIMR Berghofer Medical Research Institute Herston QLD Australia.

Ross S Francis (RS)

Department of Nephrology Princess Alexandra Hospital Woolloongabba QLD Australia.
School of Medicine University of Queensland Brisbane QLD Australia.

Dillon Corvino (D)

QIMR Berghofer Centre for Immunotherapy and Vaccine Development Tumour Immunology Laboratory QIMR Berghofer Medical Research Institute Herston QLD Australia.
School of Medicine University of Queensland Brisbane QLD Australia.

Sriganesh Srihari (S)

QIMR Berghofer Centre for Immunotherapy and Vaccine Development Tumour Immunology Laboratory QIMR Berghofer Medical Research Institute Herston QLD Australia.

Blake T Aftab (BT)

Department of Preclinical and Translational Sciences Atara Biotherapeutics Los Angeles CA USA.

Corey Smith (C)

QIMR Berghofer Centre for Immunotherapy and Vaccine Development Tumour Immunology Laboratory QIMR Berghofer Medical Research Institute Herston QLD Australia.

Rajiv Khanna (R)

QIMR Berghofer Centre for Immunotherapy and Vaccine Development Tumour Immunology Laboratory QIMR Berghofer Medical Research Institute Herston QLD Australia.
School of Medicine University of Queensland Brisbane QLD Australia.

Classifications MeSH